Detectability of small liver metastases with gadolinium BOPTA

Progress in ultrasmall ferrite nanoparticles enhanced T1 magnetic resonance angiography

Contrast-enhanced magnetic resonance angiography (CE-MRA) plays a critical role in diagnosing and monitoring various vascular diseases. Achieving high-sensitivity detection of vascular abnormalities in CE-MRA depends on the properties of contrast agents. In contrast to clinically used gadolinium-based contrast agents (GBCAs), the new generation of ultrasmall ferrite nanoparticles-based contrast agents have high relaxivity, long blood circulation time, easy surface functionalization, and high biocompatibility, hence showing promising prospects in CE-MRA. This review aims to comprehensively summarize the advancements in ultrasmall ferrite nanoparticles-enhanced MRA for detecting vascular diseases. Additionally, this review also discusses the future clinical translational potential of ultrasmall ferrite nanoparticles-based contrast agents for vascular imaging. By investigating the current status of research and clinical applications, this review attempts to outline the progress, challenges, and future directions of using ultrasmall ferrite nanoparticles to drive the field of CE-MRA into a new frontier of accuracy and diagnostic efficacy.

Liver-specific agents for contrast-enhanced MRI: role in oncological imaging

Liver-specific magnetic resonance (MR) contrast agents are increasingly used in evaluation of the liver. They are effective in detection and morphological characterization of lesions, and can be useful for evaluation of biliary tree anatomy and liver function. The typical appearances and imaging pitfalls of various tumours at MR imaging performed with these agents can be understood by the interplay of pharmacokinetics of these contrast agents and transporter expression of the tumour. This review focuses on the applications of these agents in oncological imaging.

Diagnostic accuracy of 3.0-Tesla rectal magnetic resonance imaging in preoperative local staging of primary rectal cancer

OBJECTIVES

To evaluate the diagnostic accuracy of 3.0-T rectal magnetic resonance imaging (MRI) in the preoperative local staging of primary rectal cancer.

MATERIALS AND METHODS

Forty-two patients with surgically and pathologically proven primary rectal cancer who underwent preoperative gadobenate dimeglumine-enhanced 3.0-T rectal MRI, were enrolled in this retrospective study. Two radiologists, who were blinded to the pathology results, independently reviewed the MR images and recorded their confidence level for determination of perirectal extension, and regional lymph node (LN) involvement using a 5-point scale. The diagnostic accuracy of each reviewer for local staging was calculated by receiver operating characteristic (ROC) curve analysis. Interobserver agreement was also calculated using linear weighted kappa statistics.

RESULTS

The diagnostic accuracy (area under the ROC curve, Az) for determining perirectal extension was for reviewer 1, 0.860 (95% confidence interval, 0.72-0.95) and for reviewer 2, 0.853 (0.71-0.94), respectively. The Az for determination of regional LN involvement was for reviewer 1, 0.902 (0.77-0.97) and for reviewer 2, 0.843 (0.70-0.94), respectively. Interobserver agreement included, respectively, good, and moderate agreement for perirectal extension, and regional LN involvement (kappa = 0.662, and 0.522, respectively).

CONCLUSIONS

3.0-T rectal MRI can provide accurate information of perirectal extension and regional LN involvement in the preoperative local staging of primary rectal cancer.

Hepatic imaging. An overview

For optimal detection and characterization of focal or diffuse liver disease, it is essential to obtain the most appropriate imaging test in the correct clinical setting. Access to clinical information and medical history is, therefore, essential. Moreover, familiarity with currently available modalities for imaging the liver [figure: see text] allows the optimal use of the technical advances in ultrasound imaging, CT scanning, MR imaging, and nuclear scintigraphy technology and contributes to improved diagnostic accuracy.

Superior diagnostic strength of combined contrast enhanced MR-angiography and MR-imaging compared to intra-arterial DSA in liver transplantation candidates

To evaluate the diagnostic value of combined contrast enhanced MRA (ce-MRA) and MRI compared to that of intra-arterial DSA (i.a.DSA) in liver transplantation, transjugular porto-systemic (TIPSS) and spleno-renal shunt candidates. 50 patients in the workup for liver transplantation underwent ce-MRA/MRI and i.a.DSA within a three days interval. Both examinations were assessed with respect to vessel anatomy and patency of the arterial, portal venous, porto-systemic collateral and systemic venous system. The results were compared with the intra-operative findings when available. Malignancy detection in ce-MRA/MRI and i.a.DSA were compared. There are no significant differences for the arterial part of the vascular supply to the liver that is important for transplantation. Although the differences for the portal system are not significant, the difference between the two techniques is of clinical importance because i.a.DSA failed to detect portal vein occlusion in 4 patients. Ce-MRA is significantly better for the detection of collaterals (p < 0.001) and the assessment of the inferior vena cava, the hepatic and the renal veins (p < 0.001). Although the detection of liver malignancy is poor in both techniques, ce-MRA/MRI is superior to i.a.DSA. This study shows that a one step diagnostic approach with a combination of ce-MRA and MRI is a valuable radiological tool with a superior diagnostic strength compared to i.a.DSA in the liver transplantation and shunt candidate. Therefore, ce-MRA/MRI should replace i.a.DSA in these patients groups.